Zymeworks outlines 2026 strategy with potential $440M milestones

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. IVBIY
9. SPY
10. FIX

Go back to Zymeworks outlines 2026 strategy with potential $440M milestones

Zymeworks Outlines Strategic Priorities and Outlook for 2026

January 11, 2026 6:00 PM EST

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and ChinaCompany well-positioned to execute new strategy compounding long-term value by integrating royalty growth, strategic acquisitions, and continued internal R&D innovation$125.0 million share repurchase plan announced in November 2025 available to reduce share countCash, cash equivalents, and marketable securities of approximately $270.6... More